RESEARCH PAPER
Cytomegalovirus (CMV) – a new prospect for prevention
 
More details
Hide details
1
Department of Virology, Medical University of Lublin
 
J Pre Clin Clin Res. 2013;7(2):118–123
KEYWORDS:
ABSTRACT:
Human cytomegalovirus (HCMV), a member of the Betaherpesvirinae subfamily of the Herpesviridae family, is a widespread pathogen. CMV is a virus usually completely harmless to healthy people; nevertheless, it is still a major cause of morbidity and mortality in immunocompromised individuals, such as organ transplant recipients (also haematopoietic stem cel transplantation) and AIDS patients. Furthermore, is a common cause of congenital infections. So far, it is not possible to take effective prevention activities, although there are high expectations in finding an effective vaccine. Understanding the detailed construction of the virus helped to create exactly harmless virus strains used for research. Progress in genetics and biotechnology allowed the carrying out of changes in the virus genome. Today, we know the different parts of the DNA code, are able to modify them, delete, and add inserts. All these actions bring us closer to achieving the objective of an effective and safe vaccine. The presented study shows the results of many different studies and attempts to find an effective vaccine against HCMV. The development direction of research is broad and includes various activities with the use of subunit vaccines, DNA vaccines, peptides and vaccines using the vectors. Some preparations are just at the beginning of a long journey for the registration of an cceptable vaccine, while others have entered into the last phase of clinical trials.
CORRESPONDING AUTHOR:
Małgorzata Polz-Dacewicz   
Department of Virology, Medical University of Lublin
 
REFERENCES (49):
1. Riley HD. History of the cytomegalovirus. South Med J. 1997; 90(2): 184–90.
2. Goodrum F, Cavines K, Zagallo P. Human cytomegalovirus persistence Cell Microbiol 2012; 14(5): 644–655.
3. Davison AJ, Dolan A, Akter A, Addison C, Dargan DJ, Alcendor DJ et al. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomagolovirus genome. J General Virol. 2003; 84:17–28. J Gen Virol. 2003; 84(1): 17–28.
4. Shikhagaie M, Mercé-Maldonado E, Isern E, Muntasell A, Alba MM,López-Botet M et al. The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the viron envelope. J Virol. 2012; 0: 4091–4101.
5. Boeckh M, Geballe AM. Cytomegalovirus: pathogen, paradigm and puzzle. J Clin Invest. 2011; 12(5): 1673–1680.
6. Tomtishen JP. Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28). Virol J. 2012; 9: 22–28.
7. Boppana S, Fowler KB. Persistence in the population: epidemiology and transmission. In: Arvin A., Campeadelli-Fiuwe g., Mocarski E. et al. Human Herpesviruses: Biology, Therapy and Immunology. Camridge University Press 2007.
8. Durlik M. Zakażenie wirusem cytomegalii u biorców przeszczepów narządowych. Nefrol Dial Pol. 2009; 13: 157–163.
9. Furmańczyk A, Durlik M. Nawrotowa choroba CMV o ciężkim przebiegu u pacjenta po przeszczepie nerki – opis przypadku. Forum Nefrol. 2010; 3(3): 169–173.
10. Limaye AP, Boeckh M. Cytomegalovirus (CMV) in critically-ill patients: pathogen or bystander? Rev Med Virol. 2010; 20(6): 372–379.
11. Cook ChH, Trgoccich J. Cytomegalovirus reactivation in critically ill immunocompetent hosts: A decade of progress and remaining challenges. Antiviral Res. 2011; 90(3): 151–159.
12. Melnick M, Sedghizadeh PP, Allem CM., Jaskol T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: Cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of causal relationship. Exp Mol Pathol. 2012; 92:118–125.
13. Gerna G, Lilleri D, Chiesa A. et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solidorgan transplantation. Am J Transplant. 2011; 11: 2463–2471.
14. Hammond SP, Martin ST, Roberts K, et al. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transpl Infect Dis. 2012; 0: 1–8.
15. Snydman DR, Limaye AP, Potera L, Zamora MR. Update and Review: Stae-of-The-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. Transplantation 2011; 43:1–17.
16. Vogel JU, Otte J, Koch F. Role of human cytomegalovirus genotype polymorphisms in AIDS patients with cytomegalovirus retinitis. Med Microbiol Immunol. 2013 Feb;202(1):37–47.
17. Elek SD, Stern H. Development of a vaccine against mental retardation cased by cytomegalovirus infection in utero. Lancet 1974; 1: 1–15.
18. Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979;160(1): 32–37.
19. Plotkin SA, Higgins R, Kurtz JB. et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58(11): 1176–1178.
20. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995; 171(1): 26 32.
21. Schleiss MR. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008; 325: 361–382.
22. Zhong J, Khanna R. Vaccine strategies against human cytomegalovirus infection. Expert Rev. Anti Infect Ther. 2007; 5(3): 449–459.
23. Gil A, Shen S, Coley S, Gibson L, Diamond DJ, Wang S, Lu S. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. Hum Vaccin Immunother. 2013; 9(10).
24. Heineman TC, Schleiss M, Bernstein DI, et al. A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis. 2006; 193(10): 1350–1360.
25. Jacobson MA, Adler SP, Sinclair E, et al. A CMV DNA vaccine primes ,for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 2009; 27(10): 1540–1548.
26. Jacobson MA, Sinclair E, Bredt B, et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine. 2006; 24(25): 5311–5319.
27. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009; 360(12): 1191–1199.
28. Pass RF. Development and evidence for efficacy of CMV glycoprotein Bvaccine with MF59 adjuvant. J Clin Virol 2009; 46(4): 73–76.
29. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011; 377(9733): 1256–1263.
30. Bernstein DI. Vaccines for cytomegalovirus. Infect Disord Drug Targets. 2011; 11(5): 514–525.
31. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010; 9(11): 1303–1314.
32. Chiurchiu’ S, Calo’ Carducci FI, Rocchi F, Simonetti A. Is HCMV vaccine an unmet need? The state ofart of vaccine development. Int J Immunopathol Pharmacol. 2013; 26(1): 15–26.
33. Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA. Vectored codelivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 2013; 31(6): 919–926.
34. Paston SJ, Dodi IA, Madrigal JA. Progress made towards the development of a CMV peptide vaccine. Hum Immunol. 2004; 65(5): 544–549.
35. Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis. 1999; 180(3): 843–846.
36. Minke JM, Fischer L, Baudu P, Guigal PM, Sindle T, Mumford JA, et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol. 2006; 111(1–2): 47–57.
37. Bernstein DI, Reap EA, Katen K. et al.: Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 2009; 28(2): 484–493.
38. Hartikka J, Bozoukova V, Morrow J, Rusalov D, Shlapobersky M. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother. 2012; 8(11): 1595–1606a.
39. Riedmann EM. Human vaccines & immunotherapeutics: news. Hum Vaccin Immunother. 2013; 9(4):722–72.
40. Temperton NJ. DNA vaccines against cytomegalovirus: current progress. Int J Antimicrob Agents. 2002; 19(3): 169–172.
41. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012; 12(4): 290–299.
42. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet. 2005; 55: 25–40.
43. Leviton M, Lacay J, Choi K, Hernandez-Alvarado N, Wey A, Schleiss M. An Attenuated Cytomegalovirus Vaccine with a Deletion of a Viral Chemokine Gene Is Protective against Congenital CMV Transmission in a Guinea Pig Model. Clin Dev Immunol. 2013; 906–948.
44. Lipińska A, Bieńkowska-Szewczyk K. Nowe szczepionki przeciw herpeswirusom i wektory herpeswirusowe w terapii człowieka. Post Mikrobiol. 2010; 49(3): 199–207(in Polish).
45. Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med. 2006; 12: 26–33.
46. Plotkin S, Plotkon B. Cytomegalovirus vaccines. In: Reddchase M. Cytomegaloviruses from molecular pathogenesis to therapy. Coister Academic Press 2012.
47. Ahlqvist J, Mocarski E. Cytomegalovirus UL103 controls virion and dense body egress. J Virol. 2011; 85(10): 5125–5135.
48. Azevedo RS, Amaku M. Modelling immunization strategies with cytomegalovirus vaccine candidates. Epidemiol Infect. 2011; 139(12):1818–1826.
49. Adler SP. Immunization to prevent congenital cytomegalovirus infection. Br Med Bull. 2013; 107: 57–68.
eISSN:1898-7516
ISSN:1898-2395